INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide \[[@R1]\]. HCC has a propensity to invade the portal vein and cause tumor thrombosis \[[@R2]\], which has been demonstrated to be one of the most adverse prognostic factors for HCC \[[@R3], [@R4]\]. Approximately 12.5-39.7% of HCC patients demonstrate gross portal vein tumor thrombus (PVTT) at the time of diagnosis \[[@R5]\]. Moreover, a median survival of 2.7-4.0 months has been reported if the tumor is left untreated \[[@R6], [@R7]\]. HCC with PVTT remains a contraindication for liver transplantation because of the high rate of tumor recurrence as well as the severe shortage of donor organs \[[@R8]\]. Thus, surgical resection may remain the only therapies offering a chance for long-term survival in these patients, and many clinicians have proposed that surgery should be recommended when it is feasible \[[@R9]--[@R15]\].

However, to date, the surgical strategy for HCC with PVTT remains controversial, and few studies have addressed this problem \[[@R10], [@R16]--[@R18]\]. One study demonstrated the superiority of en bloc resection compared with peeling off resection for PVTT \[[@R19]\], although other investigators have questioned the validity of this finding because no differences in HCC recurrence or overall survival (OS) rates were identified between the two groups following resection with a curative intent \[[@R17], [@R18]\]. Unfortunately, the statistical power of these previously reported studies was limited, and no case-matched or randomized clinical trials have compared the outcomes of peeling off and en bloc resection for HCC with PVTT. Thus, the optimal surgical resection method for PVTT has not yet been determined.

In the present study, the outcomes of peeling off and en bloc resections with a curative intent for PVTT were investigated, using propensity score matching to select subjects in each group to minimize the bias that arises from patient backgrounds.

RESULTS {#s2}
=======

Patients {#s2_1}
--------

A total of 2,317 patients with HCC underwent hepatic resection at Sun Yat-sen University Cancer Center between 2005 and 2012. Three hundred and two patients had evidence of macroscopic vascular invasion and underwent primary resection. 50 patients did not fulfill the inclusion criteria and were excluded from the study. In the end, 252 patients (113 patients in the en bloc group and 139 patients in the peeling off group) were enrolled in the study (Figure [1](#F1){ref-type="fig"}).

![Flowchart of the study treatments](oncotarget-07-38845-g001){#F1}

Before matching, the median follow-up period was 15.3 months (range, 0.2-108.0 months) for the en bloc group and 9.6 months (range, 0.3-107.9 months) for the peeling off group. Compared with patients in the en bloc group, patients in the peeling off group exhibited higher rate of male (96% *vs*. 88%, *P* = 0.034), higher percentage of liver cirrhosis (57% *vs*. 42%, *P* = 0.023), higher AST levels (63.8 *vs*. 54.3 U/L, *P* = 0.068), greater MELD score (5.4 *vs*. 4.6, *P* = 0.034). The baseline patient characteristics before and after propensity score matching were summarized in Table [1](#T1){ref-type="table"}. After matching, there was no significant difference between the en bloc and peeling off groups as shown in Table [1](#T1){ref-type="table"}. The operative data are summarized in Table [2](#T2){ref-type="table"} according to the surgical resection method for PVTT. No significant difference was identified between the en bloc and peeling off groups with the exception of the time of Pringle\'s maneuver; the peeling off group had a significantly longer time of Pringle\'s maneuver compared with the en bloc group (*P* = 0.003).

###### Baseline characteristics of patients before and after propensity score matching analysis

  Characteristic                                     Before Matching   After Matching                   
  ---------------------------------- --------------- ----------------- ---------------- --------------- -------
  **Epidemiology**                                                                                      
  Age (y)                            49.1 ± 11.2     47.2 ± 10.8       0.168            47.7 ± 11.3     0.325
  Gender (Male/female)               99/14 (88/12)   133/6 (96/4)      0.034            107/6 (95/5)    0.101
  **Etiology**                                                                                          0.313
   Virus (HBV/HCV)                   96 (85)         127 (91)          0.165            102 (90)        0.313
   Others                            17 (15)         12 (9)                             11 (10)         
  **Liver function**                                                                                    
  Liver cirrhosis (yes/no)           47/66 (42/58)   79/60 (57/43)     0.023            55/58 (49/51)   0.349
  PLT (10^9^/L)                      209.1 ± 83.6    201.1 ± 72.4      0.415            205.4 ± 70.7    0.722
  PT (sec)                           12.4 ± 1.4      12.6 ± 1.3        0.255            12.6 ± 1.3      0.390
  AST (U/L)                          54.3 ± 30.8     63.8 ± 48.2       0.068            56.0 ± 32.0     0.682
  ALB (g/L)                          41.2 ± 3.9      40.9 ± 3.8        0.626            40.9 ± 3.5      0.476
  TBIL (mmol/L)                      19.1 ± 34.0     23.5 ± 44.8       0.393            22.0 ± 43.0     0.579
  MELD score                         4.6 ± 3.1       5.4 ± 2.8         0.034            5.0 ± 2.7       0.226
  **Tumor burden**                                                                                      
  Tumor size (cm)                    8.5 ± 4.1       8.5 ± 2.9         0.900            8.6 ± 2.9       0.852
  Tumor number (1/\>1)               96/17 (85/15)   121/18 (87/13)    0.768            97/16 (85/15)   1.000
  Tumor extent (unilobar/ bilobar)   106/7 (94/6)    127/12 (91/9)     0.625            104/9 (92/8)    0.795
  AFP (≤/\>200) (ng/mL)              38/75 (34/66)   39/100 (28/72)    0.414            32/81 (28/72)   0.472
  Degree of PVTT (Type I/II)         48/65 (42/58)   57/82 (41/59)     0.915            47/66 (42/58)   1.000

Variables are expressed as the mean ± SD or no. (%), unless otherwise indicated;

PLT, platelet count; PT, prothrombin time; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombosis.

###### Operative results of patients in the en bloc and peeling off groups

  Characteristic                            Before Matching   After Matching                           
  ----------------------------------------- ----------------- ---------------- ------- --------------- -------
   Surgical margin (\<1/≥1 cm)              49/64 (43/57)     79/60 (57/43)    0.045   63/50 (56/44)   0.083
  Hepatectomy (non-anatomical/anatomical)   48/65 (42/58)     77/62 (68/32)    0.056   63/50 (56/44)   0.062
   Surgical time (min)                      202.8 ± 75.6      206.2 ± 76.0     0.723   198.8 ± 69.6    0.676
  Time of Pringle\'s maneuver (min)         17.0 ± 14.0       22.3 ± 13.8      0.003   22.4 ± 13.2     0.003
   Estimated blood loss (mL)                697.3 ± 696.2     758.6 ± 737.4    0.502   745.1 ± 732.4   0.616
  Red blood cell transfusion (mL)           283.6 ± 764.3     294.5 ± 908.6    0.920   308.2 ± 991.3   0.835
  Tumor capsule (yes/no)                    51/62 (45/55)     64/75 (46/54)    0.986   53/60 (47/53)   0.894
   Edmondson grades (I, II/III, IV)         50/63 (44/56)     64/75 (46/54)    0.875   50/63 (44/56)   1.000

Overall and disease-free survival {#s2_2}
---------------------------------

Before matching, 69/113 (61.1%) patients in the en bloc group and 106/139 (76.3%) patients in the peeling off group had died at the time of the primary survival analysis. The respective 1-, 3-, and 5-year OS rates were 68.9%, 34.3%, and 30.8% while the median survival time was 18.2 months for the en bloc group. In contrast, the respective 1-, 3-, and 5-year OS rates were 46.2%, 22.2%, and 17.1% while the median survival time was 10.9 months for the peeling off group. There were significant differences in the OS rates between the two groups (*P* = 0.006) (Figure [2A](#F2){ref-type="fig"}). The 1-, 2-, and 3-year disease-free survival (DFS) rates and the median DFS time were 23.6%, 19.9%, 16.1%, and 3.7 months, respectively, for the en bloc group and 18.8%, 8.9%, 7.9%, and 2.4 months, respectively, for the peeling off group. Among these patients, there were significant differences in DFS between the en bloc and peeling off groups (*P* = 0.009) (Figure [2B](#F2){ref-type="fig"}).

![Overall survival (A) and disease-free survival (B) curves of patients in the en bloc group compared with those in the peeling off group before propensity score matching analysis](oncotarget-07-38845-g002){#F2}

The 88/113 (77.9%) patients in the peeling off group had died at the time of the primary survival analysis after matching. The respective 1-, 3-, and 5-year OS rates and the median survival time were 49.1%, 22.1%, 15.8%, and 13.1 months, respectively, for the peeling off group. There were significant differences in the OS rates between the en bloc and peeling off groups (*P* = 0.011) (Figure [3A](#F3){ref-type="fig"}). The 1-, 2-, and 3-year DFS rates and the median DFS time were 19.6%, 8.4%, 7.2%, and 2.6 months, respectively, for the peeling off group. Among these patients, there were significant differences in DFS between the en bloc and peeling off groups (*P* = 0.015) (Figure [3B](#F3){ref-type="fig"}).

![Overall survival (A) and disease-free survival (B) curves of patients in the en bloc group compared with those in the peeling off group after propensity score matching analysis](oncotarget-07-38845-g003){#F3}

Recurrence and treatment for recurrent HCC {#s2_3}
------------------------------------------

Before matching, HCC recurrence was identified in 93/113 patients (82.3%) in the en bloc group and 127/139 patients (91.4%) in the peeling off group during the follow-up period. After matching, HCC recurrence was identified in 104/113 patients (92.0%) in the peeling off group. The recurrence rate in the peeling off group was higher than that in the en bloc group, although no significant difference was identified between the two groups (before matching, 91.4% *vs*. 82.3%, respectively, *P* = 0.099; after matching, 92.0% *vs*. 82.3%, respectively, *P* a significantly increased recurrence of vascular invasion compared with the en bloc group (before matching, 21.6% *vs*. 9.7%, respectively, *P* = 0.018; after matching, 23.9% *vs*. 9.7%, respectively, *P* = 0.005). The initial treatments used for recurrent HCC between the two groups are shown in Table [3](#T3){ref-type="table"} (before matching, *P* = 0.138; after matching, *P* = 0.211).

###### Recurrence and treatment for the en bloc and peeling off groups

  Variable                                                        Before Matching                After Matching                
  --------------------------------------------------------------- ----------------- ------------ ---------------- ------------ -------
  **Recurrence type**[\*](#tfn_001){ref-type="table-fn"}**, n**   93 (82.3)         127 (91.4)   0.099            104 (92.0)   0.081
  Intrahepatic recurrence                                         77                109          0.089            89           0.098
  Extrahepatic metastasis                                         29                42           0.510            34           0.553
  Vascular invasion                                               11                30           0.018            27           0.005
  **Treatment for the first recurrence, (n)**                                                    0.138                         0.211
  TACE                                                            49                78                            58           
  Resection                                                       1                 1                             1            
  Local ablation                                                  3                 2                             2            
  Systemic chemotherapy                                           3                 0                             0            
  Sorafenib                                                       1                 3                             3            

Some patients had more than one type of recurrence.

Mortality and morbidity {#s2_4}
-----------------------

Mortality and complications are summarized in Table [4](#T4){ref-type="table"}. Three patients in the en bloc group died as a result of abdominal infection and liver failure after the operation. Additionally, one patient in the peeling off group died from a postoperative biliary fistula infection accompanied by hepatic encephalopathy. However, both before and after matching, there were no significant differences between the two groups regarding postoperative complications and mortality.

###### Mortality and complications for the en bloc and peeling off groups

  Mortality and Complications                                   Before Matching   After Matching                
  ------------------------------------------------------------- ----------------- ---------------- ------- ---- -------
  **Complications**[\*](#tfn_002){ref-type="table-fn"}**, n**                                                   
  I                                                             7                 10               0.753   9    0.604
   II                                                           18                17               0.398   15   0.572
  III                                                           10                12               0.952   11   0.819
  IV                                                            3                 1                0.328   1    0.622
  90-day mortality                                              3                 1                0.328   1    0.622

According to Dindo et al. Classification \[[@R38]\].

Univariate and multivariate analyses of overall survival and disease-free survival for patients before and after the propensity score matching analysis {#s2_5}
-------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the influence of surgical resection variables on patient OS and DFS, the variables listed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} were included in the univariate analysis. Before matching, in the multivariate analysis, the thrombectomy method (hazard ratio (HR) = 1.553; 95% confidence interval (CI), 1.146-2.106; *P* = 0.005) and degree of PVTT (HR = 1.418; 95% CI, 1.043-1.928; *P* = 0.026) were identified as independent predictors of OS (Table [5](#T5){ref-type="table"}). The thrombectomy method (HR = 1.444; 95% CI, 1.104-1.890; *P* = 0.007) and the alpha-fetoprotein level (HR = 1.412; 95% CI, 1.057-1.885; *P* = 0.019) were identified as independent predictors of DFS (Table [5](#T5){ref-type="table"}).

###### Univariate and multivariate analyses of overall survival and disease-free survival for patients before propensity score matching analysis

  Variable                                    Overall Survival   Disease-free Survival                                                 
  ------------------------------------------- ------------------ ----------------------- ------- ------------- ------- ------- ------- -------------
  Age (y), ≤/\>50                             0.087                                                            0.024                   
  Gender (male/female)                        0.826                                                            0.107                   
  Etiology (virus/others)                     0.077                                                            0.155                   
  Liver cirrhosis (yes/no)                    0.240                                                            0.674                   
  PLT (10^9^/L), ≤/\>100                      0.622                                                            0.339                   
  PT (sec), ≤/\>13                            0.209                                                            0.860                   
  AST (U/L), ≤/\>45                           0.316                                                            0.090                   
  ALB (g/L), ≤/\>35                           0.757                                                            0.277                   
  TBIL (mmol/L), ≤/\>17                       0.650                                                            0.888                   
  MELD score, ≤/\>5                           0.648                                                            0.591                   
  Tumor size (cm), ≤/\>5                      0.024                                                            0.212                   
  Tumor number, ≤/\>1                         0.207                                                            0.491                   
  Tumor extent (unilobar/ bilobar)            0.559                                                            0.762                   
  AFP (ng/mL), ≤/\>200                        0.078                                                            0.024   0.019   1.412   1.057-1.885
  Degree of PVTT (Type I/II)                  0.035              0.026                   1.418   1.043-1.928   0.124                   
  Surgical margin (\<1/≥1 cm)                 0.036                                                            0.050                   
  Hepatectomy (non-anatomical /anatomical)    0.643                                                            0.384                   
  Surgical time (min), ≤/\>200                0.281                                                            0.331                   
  Estimated blood loss (mL), ≤/\>700          0.325                                                            0.699                   
  Blood transfusion (mL), ≤/\>300             0.099                                                            0.102                   
  Time of Pringle\'s maneuver (min), ≤/\>20   0.486                                                            0.326                   
  Tumor capsule (yes/no)                      0.521                                                            0.475                   
  Edmondson grades (I, II/III, IV)            0.307                                                            0.791                   
  Thrombectomy (en bloc/peeling off)          0.006              0.005                   1.553   1.146-2.106   0.009   0.007   1.444   1.104-1.890

PLT, platelet count; PT, prothrombin time; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombosis.

###### Univariate and multivariate analyses of overall survival and disease-free survival for patients after propensity score matching analysis

  Variable                                    Overall Survival   Disease-free Survival                                                 
  ------------------------------------------- ------------------ ----------------------- ------- ------------- ------- ------- ------- -------------
  Age (y), ≤/\>50                             0.128                                                            0.036                   
  Gender (male/female)                        0.926                                                            0.127                   
  Etiology (virus/others)                     0.175                                                            0.368                   
  Liver cirrhosis (yes/no)                    0.477                                                            0.993                   
  PLT (10^2^/L), ≤/\>100                      0.350                                                            0.560                   
  PT (sec), ≤/\>13                            0.318                                                            0.710                   
  AST (U/L), ≤/\>45                           0.244                                                            0.071                   
  ALB (g/L), ≤/\>35                           0.695                                                            0.380                   
  TBIL (mmol/L), ≤/\>17                       0.849                                                            0.559                   
  MELD score, ≤/\>5                           0.892                                                            0.928                   
  Tumor size (cm), ≤/\>5                      0.016              0.025                   1.435   1.046-1.969   0.185                   
  Tumor number, ≤/\>1                         0.242                                                            0.591                   
  Tumor extent (unilobar/ bilobar)            0.246                                                            0.519                   
  AFP (ng/mL), ≤/\>200                        0.204                                                            0.024                   
  Degree of PVTT (Type I/II)                  0.051                                                            0.109                   
  Surgical margin (\<1/≥1 cm)                 0.067                                                            0.049                   
  Hepatectomy (non-anatomical /anatomical)    0.819                                                            0.280                   
  Surgical time (min), ≤/\>200                0.577                                                            0.488                   
  Estimated blood loss (mL), ≤/\>700          0.187                                                            0.571                   
  Blood transfusion (mL), ≤/\>300             0.073                                                            0.089                   
  Time of Pringle\'s maneuver (min), ≤/\>20   0.391                                                            0.368                   
  Tumor capsule (yes/no)                      0.519                                                            0.554                   
  Edmondson grades (I, II/III, IV)            0.208                                                            0.720                   
  Thrombectomy (en bloc/peeling off)          0.011              0.017                   1.471   1.071-2.018   0.015   0.016   1.415   1.068-1.874

PLT, platelet count; PT, prothrombin time; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombosis.

The thrombectomy method (HR = 1.471; 95% CI, 1.071-2.018; *P* = 0.017) and tumor size (HR = 1.435; 95% CI, 1.046-1.969; *P* = 0.025) were identified as independent predictors of OS after matching as shown by the multivariate analysis. The thrombectomy method (HR = 1.415; 95% CI, 1.068-1.874; *P* = 0.016) was identified as an independent predictor of DFS.

DISCUSSION {#s3}
==========

Prognosis remains poor for HCC patients with macrovascular PVTT \[[@R6]\]. Specifically, PVTT can lead to broad dissemination of the tumor throughout the liver and exacerbate portal hypertension, which may result in liver failure or life-threatening variceal bleeding \[[@R5]\]. Hepatic resection may be the last option for these patients. Several studies have reported that radical resection of the tumor and involved vessels can prolong survival and may even offer a chance of cure in selected cases \[[@R9], [@R20]--[@R22]\]. However, there is little consensus regarding the optimum treatment strategy for HCC patients with PVTT. In our study, we demonstrate that en bloc resection contributes to better OS and DFS after initial surgery in cases with HCC and PVTT. These findings suggest that en bloc resection may be superior to peeling off resection as an operative procedure for HCC patients with PVTT. Although three previous studies have compared the survival outcomes between en bloc and peeling off resections for HCC with PVTT, to our knowledge, our study comprises the largest study population and presents the longest follow-up data reported to date \[[@R17]--[@R19]\]. In addition, the current findings, which were obtained after balancing patient demographics, liver function reserves, and tumor characteristics between the en bloc and peeling off groups, provide important data that may be used to establish an optimal surgical strategy for the management of HCC patients with PVTT.

For HCC patients with PVTT, the en bloc technique, in which PVTT is resected together with the PVTT-bearing territory (internal wall of its portal vein), may be regarded as the only curative method available \[[@R18]\]. Potential reasons for misgivings regarding this technique are that the en bloc technique is a relatively complicated procedure and leads to a greater loss of liver parenchyma and blood. However, the present study demonstrated that en bloc and peeling off resections were not significantly different in terms of hospital mortality and morbidity, which is similar to previous studies \[[@R16], [@R17]\]. The peeling off technique, in which the PVTT is resected but the PVTT-bearing territory is preserved, may increase the risk of cancer cell residue on the portal venous wall. Indeed, because of a high incidence of intramural infiltration of cancer cells at the adhesion site of the portal vein cuff, the direct removal of thrombi in the portal vein could not be regarded as a curative resection for HCC \[[@R16]\]. Our study confirmed that the peeling off group showed a significantly increased recurrence of vascular invasion compared with the en bloc group (before matching, 21.6% *vs*. 9.7%, respectively, *P* = 0.018; after matching, 23.9% *vs*. 9.7%, respectively, *P* = 0.005). In addition, according to our multivariate analysis, en bloc thrombectomy was an independent prognostic factor for OS and DFS with the largest HR, which suggests that this procedure results in significantly better survival compared with peeling off thrombectomy. Thus, the entire thrombi-adhering segment of the portal vein should be resected in HCC patients with PVTT.

Anatomical resection is theoretically superior to non-anatomical resection because anatomical resection can eradicate the main tumor as well as micrometastases or microsatellite lesions along the portal tributaries; however, the clinical significance of these differences remains controversial \[[@R23], [@R24]\]. Several reports have demonstrated the effectiveness of anatomical resection for HCC in terms of postoperative recurrence and survival \[[@R23], [@R25]--[@R28]\]. In contrast, other reports have demonstrated no obvious superiority of anatomical resection compared with non-anatomical resection \[[@R24], [@R29], [@R30]\]. To date, the clinical benefit of anatomical resection even for early HCC remains controversial. For HCC patients with PVTT, anatomical resection showed no advantage compared with non-anatomical resection regarding postoperative outcomes in our study, consistent with previous studies \[[@R31], [@R32]\]. The resection margin has also been evaluated as a prognostic factor for long-term outcomes after HCC resection; however, the significance of this variable also remains controversial \[[@R19], [@R32], [@R33]\]. Our previous study explored patterns of intrahepatic micrometastasis using large pathological sections of liver resection specimens from 113 patients with solitary HCC \[[@R34]\]. We determined that the spread of the tumor satellite micronodules ranged from 0.1 to 0.8 cm, whereas the spread of the intravascular micrometastases ranged from 0.05 to 6.1 cm. We believe that dissemination *via* microscopic portal vein invasion cannot be controlled by extensive anatomic surgeries with wider resection margins \[[@R35]\]. In addition, patients with PVTT typically have injured livers; thus, extensive hepatic resection may cause serious postoperative liver failure, which is among the most common lethal complications of this procedure.

This study had several limitations, the most important of which was the lack of randomization. Instead, the treatment choices were determined in consideration of various clinical factors, which likely led to potential selection bias in our population. However, this bias was limited by the similar baseline characteristics between the two groups using propensity score matching analysis. Second, our study excluded patients who were diagnosed with PVTT that extended to the main portal vein (type III PVTT) or the contralateral portal vein. For these patients, resection remains controversial and is typically not recommended because of the high surgical mortality and low survival benefit \[[@R9], [@R15]\].

In conclusion, this study demonstrates that en bloc resection confers a survival advantage over peeling off resection for HCC patients with PVTT. Thus, en bloc resection represents the optimal surgical strategy for the management of HCC patients with PVTT and should be recommended as a standard treatment for these patients when possible.

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

Between January 2005 and December 2012, treatment-naive patients with HCC who received first-line therapy with hepatic resection were retrospectively reviewed from a prospectively registered databank at Sun Yat-sen University Cancer Center. Only patients who had undergone hepatic resection with curative intent (R0) and had been pathologically diagnosed with macroscopic PVTT were screened for eligibility in the study (Figure [1](#F1){ref-type="fig"}).

The presence of PVTT was identified by preoperative imaging (Doppler ultrasound, contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) or intra-operative ultrasound (IOUS)), naked eye observations during operation, and pathological examination. All patients diagnosed with HCC and PVTT were histopathologically confirmed in the resected specimens. According to previous reports \[[@R12], [@R36]\], the degree of PVTT was divided into 3 types based on the intraoperative findings. In type I, the tumor thrombi involve the segmental branches of the portal vein or above; in type II, the tumor thrombi extend to include the right/left portal vein; and, in type III, the main portal vein is involved.

The patients underwent the following examinations before surgery: routine blood chemistry tests, indocyanine green retention rate in 15 min (ICG-R15), color Doppler ultrasonography, and CT or MRI of the abdomen and chest. Patients were excluded from the study if they had one or more of the following conditions: (a) extrahepatic metastasis and main portal vein (type III PVTT) or contralateral portal vein tumor thrombosis; (b) Child-Pugh class B or C; (c) palliative tumor resection; or (d) incomplete data or loss to follow-up.

This study complied with the Health Insurance Portability and Accountability Act regulations and was approved by the Ethics Committee of the Cancer Center. Written informed consent was obtained from all patients in this study.

Hepatic resection procedure {#s4_2}
---------------------------

The techniques for hepatic resection were performed as our previously described \[[@R13], [@R36]\]. IOUS was routinely performed, and Pringle\'s maneuver was applied to occlude the liver\'s blood inflow. Anatomic hepatic resection with en bloc thrombectomy was our preferred surgical method for liver resection. As an alternative, non-anatomical resection was used in cases of intolerable en bloc wide resection. For each patient, the decision to perform major or minor resection was made pre-operatively on the basis of tumor location on preoperative imaging, liver functions of the patient, Child-Pugh status, indocyanine green retention at 15 min (ICG 15), and the likelihood of achieving an adequate resection margin. The treatment choice was ultimately determined by our multidisciplinary treatment team, which included radiologists, surgeons and oncologists \[[@R36]\]. The operative procedure and the location at which the portal branch should be ligated were determined preoperatively based on the liver functional reserve and the extent of the tumor itself, not the extent of the PVTT. The surgical management for PVTT was ultimately determined based on the findings of IOUS. If the portal branch could be ligated with a sufficient safety margin between its root and the tip of the PVTT, the en bloc technique was utilized. If the PVTT extended beyond the root of the portal branch to be ligated, the PVTT was extracted from the opened stump of the portal vein branch (peeling-off technique) \[[@R18]\]. With the en bloc method, macroscopic exposure of the PVTT did not occur. The portal vein was ligated at 2 different points with an adequate safety margin from the tip of the PVTT, and the section of the vein between the 2 ligations was divided (conventional en bloc technique). If a 2-point ligation was difficult because of a short distance to the branching site, a single ligation was placed at the branching site and the vein was carefully divided without injuring the PVTT during the final stage of liver transection (modified en bloc technique). With the peeling off technique, the portal venous wall was opened and separated from the PVTT and the PVTT was removed. The PVTT should be extracted before mobilization and transection of the liver to minimize the intraoperative migration of the tumor thrombus into the future remnant liver. After flushing with normal saline and confirming that no PVTT remained, the stump was closed with a continuous suture.

Subsequent treatment {#s4_3}
--------------------

Recurrence after surgery was defined as the appearance of a new lesion with radiologic features typical of HCC, as confirmed by two or more imaging modalities. For patients who developed tumor recurrence, the treatment choice was determined by the characteristics of the recurrent tumor, the patient\'s request, and discussion among our multidisciplinary team \[[@R13], [@R37]\]. Conservative treatments were provided for patients with terminal HCC, Child-Pugh C liver function, or ECOG scores \> 2.

Follow-up {#s4_4}
---------

Follow-up examinations were conducted *via* laboratory findings (including serum alpha-fetoprotein (AFP), liver function, and blood tests), abdominal ultrasonography, and contrast-enhanced CT. The first CT was performed 4 weeks after surgery, every 3 months for the first year and every 6 months thereafter for a total of 60 months after treatment. The Complications was reported based on Clavien-Dindo classification \[[@R38]\]. Treatment mortality was defined as death within 90 days after surgery. The study was censored on August 31, 2015.

Propensity score matching analysis {#s4_5}
----------------------------------

The demographic, preoperative and tumor variables were compared between the peeling off and en bloc groups. The operative approach was not randomly assigned; thus, there was a potential for confounding and selection bias between the two groups. Therefore, propensity score matching was conducted prior to comparisons of OS and DFS between the peeling off and the en bloc propensity score-matched groups.

Preoperative variables potentially affecting the outcomes were assigned propensity scores \[[@R39]\]. We employed a logistic regression model to estimate propensity scores, using the following baseline characteristics as covariates in the model: age (≤50/ \> 50 y), gender (male/female), etiology (virus/other), liver cirrhosis (yes/no), platelet count (≤100/ \> 100\*10^9^/L), prothrombin time (≤13/ \> 13 sec), aspartate aminotransferase (≤45/ \> 45 U/L), albumin (≤35/ \> 35 g/L), total bilirubin (≤17/ \> 17 mmol/L), model for end-stage liver disease (MELD) score (≤5/ \> 5), tumor size (≤5/ \> 5 cm), tumor number (≤1/ \> 1), tumor extent (unilobar/bilobar), AFP (≤200/ \> 200 ng/ml), and degree of PVTT (Type I/II). Subsequently, a one-to-one match between the en bloc resection group and peeling off resection group was obtained by use of the nearest neighbor matching with the caliper width of 0.01 and without replacement \[[@R40]\]. Statistical analysis was performed using SPSS (IBM SPSS Statistics for Windows, Version 20.0. IBM Corp., Armonk, NY) and Propensity Score Matching for SPSS, version 1.0 (Felix Thoemmes, Cornell University/University of Tübingen).

Statistical analysis {#s4_6}
--------------------

The primary outcome measures were OS and DFS. OS was calculated from the date of diagnosis until death or the end of the follow-up period. In this study, DFS was defined as the interval between the operation and the date of diagnosis of the first recurrence or the last follow-up. The secondary outcome measures included procedure-related complications and tumor recurrence type. The cutoff values of the continuous variables were based on those commonly used in previous studies or were dichotomized using normal reference values. For comparisons between the baseline variables, Student\'s t test for continuous variables and a χ2 test for categorical variables were used. Survival curves and univariate analysis were conducted using the Kaplan-Meier method, and the differences were analyzed *via* the log-rank test. The prognostic factors identified as significant in the univariate analysis (*P* \< 0.1) were subjected to multivariate analysis with the Cox proportional hazards regression model. A statistically significant difference was set at *P* \< 0.05.
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